Fenofibrate: treatment of hyperlipidemia and beyond

References

• National Cholesterol Education Panel (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. Circulation106(25), 3143–3421 (2002).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes–2008. Diabetes Care31(Suppl. 1), S12–S54 (2008).
   PubMed Web of Science ®Google Scholar
• Smith SC, Allen J, Blair SN et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation113(19), 2363–7232 (2006).
   PubMed Web of Science ®Google Scholar
• Buse JB, Ginsberg HN, Bakris GL et al.; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus. A scientific statement from the American Heart Association and the American Diabetes Association. Circulation115(1), 114–126 (2007).
   PubMed Web of Science ®Google Scholar
• Brunzell JD, Davidson M, Furberg CD et al. Lipoprotein management in patients with cardiometabolic risk. Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care31(4), 811–822 (2008).
   PubMed Web of Science ®Google Scholar
• Graham I, Atar B, Borch-Johnsen K et al.; Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Executive summary. Eur. Heart J.28(19), 2375–2414 (2007).
   PubMed Web of Science ®Google Scholar
• Ryden L, Standl E, Bartnik M et al.; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes and cardiovascular disease: executive summary. Eur. Heart J.28(1), 88–136 (2007).
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM et al.; Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet366(9493), 1267–1278 (2005).
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet371(9607), 117–125 (2008).
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med.352(14), 1425–1435 (2005).
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med.350(15), 1495–1504 (2004).
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Sacks F, Hermans MP et al. Executive statement, The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidemic patients. Diab. Vasc. Dis. Res.(2008) (In Press).
   Google Scholar
• Ninomiya JK, L’Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation109(1), 42–46 (2004).
   PubMed Web of Science ®Google Scholar
• Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of Type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J. Clin. Endocrinol. Metab.89(6), 2601–2607 (2004).
   PubMed Web of Science ®Google Scholar
• Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature414(6865), 782–787 (2001).
   PubMed Web of Science ®Google Scholar
• Meyers CD, McCarren M, Wong ND et al.; VADT Investigators. Baseline achievement of lipid goals and usage of lipid medications in patients with diabetes mellitus (from the Veterans Affairs Diabetes Trial). Am. J. Cardiol.98(1), 63–65 (2006).
   PubMedGoogle Scholar
• Kemp TM, Barr ELM, Zimmet PZ et al. Glucose, lipid, and blood pressure control in Australian adults with Type 2 diabetes. The 1999–2000 AusDiab. Diabetes Care28(6), 1490–1492 (2005).
   PubMedGoogle Scholar
• Keating GM, Croom F. Fenofibrate. A review of its use in primary dyslipidaemia, the metabolic syndrome and Type 2 diabetes mellitus. Drugs67(1), 121–153 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenson RS. Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in Type 2 diabetes. Am. J. Cardiol.99(4 Suppl. 1), B96–B104 (2007).
   PubMed Web of Science ®Google Scholar
• Fruchart J-C, Duriez P. Mode of action of fibrates in the regulation of triglycerides and HDL-cholesterol metabolism. Drugs Today42(1), 39–64 (2006).
   PubMed Web of Science ®Google Scholar
• Wagner JA, Larson PJ, Weiss S et al. Individual and combined effects of peroxisome proliferator-activated receptor α and γ agonists, fenofibrate and rosiglitazone, on biomarkers of lipid and glucose metabolism in healthy nondiabetic volunteers. J. Clin. Pharmacol.45(5), 504–513 (2005).
   PubMedGoogle Scholar
• Hogue JC, Lamarche B, Deshaies Y et al. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with Type 2 diabetes mellitus with marked hypertriglyceridemia. Metabolism57(3), 246–254 (2008).
   PubMed Web of Science ®Google Scholar
• Vega GL, Cater B, Hadizadeh DR 3rd, Meguro S, Grundy SM. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome. Clin. Pharmacol. Ther.74(3), 236–244 (2003).
   PubMedGoogle Scholar
• Rosenson RS, Wolff DA, Huskin AL, Helenowsi IB, Rademaker AW. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinaemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care (8), 1945–1951 (2007).
   PubMedGoogle Scholar
• Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA298(3), 309–316 (2007).
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA298(3), 299–308 (2007).
   PubMed Web of Science ®Google Scholar
• Hiukka A, Leinonen E, Jauhiainen M et al. Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with Type 2 diabetes mellitus. Diabetologia50(10), 2067–2075 (2007).
   PubMed Web of Science ®Google Scholar
• Vakkilainen J, Steiner G, Ansquer J-C et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease. Circulation107(13), 1733–1737 (2003).
   PubMed Web of Science ®Google Scholar
• Davidson MH, Bays HE, Stein E et al.; TRIMS Investigators. Effects of fenofibrate on atherogenic dyslipidaemia in hypertriglyceridemic subjects. Clin. Cardiol.29(6), 268–273 (2006).
   PubMed Web of Science ®Google Scholar
• May HT, Anderson JL, Pearson RR et al. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidaemia (from the Diabetes and Combined Lipid Therapy Regimen Study). Am. J. Cardiol.101(4), 486–489 (2008).
   PubMed Web of Science ®Google Scholar
• van der Hoogt CC, de Haan W, Westerterp M et al. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. J. Lipid Res.48(8), 1763–1771 (2007).
   Google Scholar
• Ikewaki K, Tohyama J, Nakata Y, Wakikawa T, Kido T, Mochizuki S. Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridaemia men–a nuclear magnetic resonance study. J. Atheroscler. Thromb.11(5), 278–285 (2004).
   PubMedGoogle Scholar
• Ooi TC, Cousins M, Ooi DS, Nakajima K, Edwards AL. Effect of fibrates on postprandial remnant-like particles in patients with combined hyperlipidaemia. Atherosclerosis172(2), 375–382 (2004).
   PubMedGoogle Scholar
• Koh KK, Quon MJ, Han SH et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J. Am. Coll. Cardiol.45(10), 1649–1653 (2005).
   PubMed Web of Science ®Google Scholar
• Rosenson RS. Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyeridemic subjects with the metabolic syndrome. Am. Heart J.155(3), 499 e9–e16 (2008).
   PubMedGoogle Scholar
• Carlquist JF, Muhlestein JB, Anderson JL. Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Rev. Mol. Diagn.7(5), 511–517 (2007).
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Gazi IF, Liberopoulos EN et al. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis193(2), 428–437 (2007).
   PubMed Web of Science ®Google Scholar
• Saougos VG, Tambaki AP, Kalogirou M et al. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler. Thromb. Vasc. Biol.27(10), 2236–2243 (2007).
   PubMed Web of Science ®Google Scholar
• Phuntuwate W, Suthisisang C, Koanantakul B, Chaloeiphap P, Mackess B, Mackess M. Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels. Atherosclerosis196(1), 122–128 (2008).
   PubMedGoogle Scholar
• Okopien B, Lrysiak R, Herman ZS. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J. Clin. Endocrinol. Metab.91(5), 1770–1778 (2006).
   PubMedGoogle Scholar
• Muhlestein JB, May HT, Jensen JR et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidaemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J. Am. Coll. Cardiol.48(2), 396–401 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Huskin AL, Wolff DA, Helenowski IB, Rademaker AW. Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridaemia patients with the metabolic syndrome. Atherosclerosis198(2), 381–388 (2008).
   PubMed Web of Science ®Google Scholar
• Koh KK, Han SH, Quon MJ, Yeal Ahn J, Shin EK. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care28(6), 1419–1424 (2005).
   PubMed Web of Science ®Google Scholar
• Rosenson RS. Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients. Obesity (2008) (In Press).
   Google Scholar
• LeBrasseur NK, Duhaney TAS, De Silva DS et al. Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension. Hypertension50(3), 489–496 (2007).
   PubMedGoogle Scholar
• Ogata T, Miyauchi T, Sakai S, Takanashi M, Iruayama-Tomobe Y, Yamaguchi I. Myocardial fibrosis and diastolic dysfunction in deoxycortiosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-α activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-κ-B pathway. J. Am. Coll. Cardiol.43(8), 1481–1488 (2004).
   PubMed Web of Science ®Google Scholar
• Li YY, McTiernan CF, Feldman AM. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc. Res.46(2), 214–224 (2000).
   PubMed Web of Science ®Google Scholar
• Ichihara S, Obata K, Yamada Y et al. Attenuation of cardiac dysfunction by a PPAR-α agonist is associated with down-regulation of redox-regulated transcription factors. J. Mol. Cell. Cardiol.41(2), 318–329 (2006).
   PubMed Web of Science ®Google Scholar
• Sam F, Xie Z, Ooi H et al. Mice lacking osteopontin exhibit increased left ventricular dilation and reduced fibrosis after aldosterone infusion. Am. J. Hypertens.17(2), 188–193 (2004).
   PubMedGoogle Scholar
• Kjekshus J, Apetrei E, Barrios V et al. Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med.357(22), 2248–2261 (2007).
   PubMed Web of Science ®Google Scholar
• Genest J Jr, Nguyen N-H, Theroux P, Davignon J, Cohn JS. Effect of micronised fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state. J. Cardiovasc. Pharmacol.35(1), 164–172 (2000).
   PubMed Web of Science ®Google Scholar
• Krempf M, Rohmer V, Farnier M et al. Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia. Diabetes Metab.26(3), 184–191 (2000).
   PubMedGoogle Scholar
• Sasaki J, Yamamoto K, Ageta M. Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidaemia: a randomized, double-blind, placebo-controlled, multicentre, crossover study. Clin. Ther.24(10), 1614–1626 (2002).
   PubMedGoogle Scholar
• Belfort RS, Berria R, DeFronzo R et al. Fenofibrate improves the atherogenic lipid profile and markers of vascular inflammation independent of changes in insulin sensitivity in hypertriglyceridemic subjects with the metabolic syndrome. Diabetologia47(Suppl. 1), A25–A26 (2004).
   Google Scholar
• Farnier M, Freeman MW, Macdonell G et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed dyslipidemia. Eur. Heart J.26(9), 897–905 (2005).
   PubMed Web of Science ®Google Scholar
• McKenney JM, Farnier M, Lo KW et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidaemia. J. Am. Coll. Cardiol.47(8), 1584–1587 (2006).
   PubMed Web of Science ®Google Scholar
• McKenney J, Jones M, Abby S. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. Curr. Med. Res. Opin.21(9), 1403–1412 (2005).
   PubMed Web of Science ®Google Scholar
• Nieuwdorp M, Stroes ES, Kastelein JJ; Fenofibrate/Metformin Study Group. Normalization of metabolic syndrome using fenofibrate, metformin or their combination. Diabetes Obes. Metab.9(6), 869–878 (2007).
   PubMedGoogle Scholar
• Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am. J. Cardiol.95(4), 462–468 (2005).
   PubMed Web of Science ®Google Scholar
• Athyros VG, Papageorgiou AA, Athyrou VV, Demitridias DS, Kontopoulos AG. Atorvastatin and micronised fenofibrate alone and in combination in Type 2 diabetes with combined hyperlipidemia. Diabetes Care25(7), 1198–1202 (2002).
   PubMed Web of Science ®Google Scholar
• Vega GL, Ma PT, Cater MB et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am. J. Cardiol.91(8), 956–960 (2003).
   PubMed Web of Science ®Google Scholar
• Scott R, Best J, Forder P et al.; The FIELD Study Investigators. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate (ISRCTN64783481). Cardiovasc. Diabetol.4, 13 (2005).
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P et al.; The FIELD study investigators. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes (the FIELD study): randomised controlled trial. Lancet366(9500), 1849–1861 (2005).
   PubMed Web of Science ®Google Scholar
• Rosenson RS. FIELD of confusion: future prospects for fibrate therapy in cardiovascular disease. Curr. Atheroscler. Rep.8(3), 219–222 (2006).
   PubMedGoogle Scholar
• The Bezafibrate Infarction Prevention (BIP) study group. Secondary prevention by raising HDL-cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) study. Circulation102(1), 21–27 (2000).
   PubMed Web of Science ®Google Scholar
• Manninen V, Tenkanen L, Koskinen P et al. Joint effects of serum triglyceride and LDL-cholesterol and HDL-cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation85(1), 37–45 (1992).
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med.341(6), 410–418 (1999).
   PubMed Web of Science ®Google Scholar
• Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch. Intern. Med.165(10), 1154–1160 (2005).
   PubMed Web of Science ®Google Scholar
• Scott R, d’Emden M, Best J et al. Features of metabolic syndrome identify individuals with Type 2 diabetes mellitus at high risk for cardiovascular events and greater absolute benefits of fenofibrate. Circulation116(II 838) (2007) (Abstract 3691).
   Google Scholar
• Keech A, Simes J, Barter P et al.; FIELD Management Committee. Correction to the FIELD study report. Lancet368(9545), 1415 (2006).
   PubMedGoogle Scholar
• Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary artery disease in Type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet357(9260), 905–910 (2001).
   PubMed Web of Science ®Google Scholar
• Zhu S, Su G, Meng QH. Inhibitory effects of micronised fenofibrate on carotid atherosclerosis in patients with essential hypertension. Clin. Chem.52(11), 2036–2042 (2006).
   PubMedGoogle Scholar
• Ginsberg HN, Bonds DE, Lovato LC et al. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am. J. Cardiol.99(12A), i56–i67 (2007).
   PubMed Web of Science ®Google Scholar
• Keech AC, Mitchell P, Summanen PA et al.; FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet370(9600), 1687–1697 (2007).
   PubMed Web of Science ®Google Scholar
• Ryan KE, McCance DR, Powell L, McMahon R, Trimble ER. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis194(2), e123–e130 (2007).
   PubMed Web of Science ®Google Scholar
• Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell. Physiol.280(6), C1358–C1366 (2001).
   PubMed Web of Science ®Google Scholar
• Kim J, Ahn JH, Yu YS et al. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Experimental Eye Res.84(5), 886–893 (2007).
   PubMed Web of Science ®Google Scholar
• Chew EY, Ambrosius WT, Howard LT et al.; ACCORD Study Group. Rationale, design and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE). Am. J. Cardiol.99(12A), i103–i111 (2007).
   PubMedGoogle Scholar
• Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G; DAIS Investigators. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in Type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am. J. Kidney Dis.45(3), 485–493 (2005).
   PubMed Web of Science ®Google Scholar
• Burgess D, Hunt D, Li L et al. Effects of fenofibrate on silent myocardial infarction, hospitalization for acute coronary syndromes and amputation in Type 2 diabetes: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Circulation116(II 838) (2007) (Abstract).
   Google Scholar
• Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am. J. Cardiol.99(Suppl.), C3–C18 (2007).
   PubMed Web of Science ®Google Scholar
• Dierkes J, Westphal S, Luley C. The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. Expert Opin. Drug Saf.3(2), 101–111 (2004).
   PubMedGoogle Scholar
• Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am. J. Cardiol.95(1), 120–122 (2005).
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab. Dispos.30(11), 1280–1287 (2002).
   PubMed Web of Science ®Google Scholar
• Backman JT, Kyrklund C, Kivisto KT, Wang JS, Neuvonen PJ. Plasma concentrations of active simvastatin are increased by gemfibrozil. Clin. Pharmacol. Ther.68(2), 122–129 (2000).
   PubMed Web of Science ®Google Scholar
• Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin. Pharmacol. Ther.73(6), 538–544 (2003).
   PubMed Web of Science ®Google Scholar
• Schneck DW, Birmingham BK, Zalikowski JA et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin. Pharmacol. Ther.75(5), 455–463 (2004).
   PubMed Web of Science ®Google Scholar
• Backman JT, Luurila H, Neuvonen M, Neuvonen PJ. Rifampicin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin. Pharmacol. Ther.78(2), 154–167 (2005).
   PubMed Web of Science ®Google Scholar
• Pan W, Gustavson LE, Achari R et al. Lack of clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J. Clin. Pharmacol.40(3), 316–323 (2000).
   PubMed Web of Science ®Google Scholar
• Bergman AJ, Murphy G, Burke J et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J. Clin. Pharmacol.44(9), 1054–1062 (2004).
   PubMed Web of Science ®Google Scholar
• Gustavson LE, Schweitzer SM, Koehne-Voss S et al. The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3α-hydroxy isomeric metabolite. J. Clin. Pharmacol.45(8), 947–953 (2005).
   PubMed Web of Science ®Google Scholar
• Martin PD, Dane AL, Schneck DW, Warwick MJ. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibric acid in healthy volunteers. Clin. Ther.25(2), 459–471 (2003).
   PubMed Web of Science ®Google Scholar
• Penn R, Williams RX 3rd, Guha-Ray DK, Sawyers WG, Braun SL, Rains KT. An open-label, cross-over study of the pharmacokinetics of insoluble drug delivery microparticle fenofibrate in combination with atorvastatin, simvastatin and extended-release niacin in healthy volunteers. Clin. Ther.28(1), 45–54 (2006).
   PubMed Web of Science ®Google Scholar
• Thompson PD, Clarkson PM, Rosenson RS; The National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel. An assessment of statin safety by muscle experts. Am. J. Cardiol.97(8A), C69–C76 (2006).
   PubMed Web of Science ®Google Scholar